Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 173
- Registration Number
- NCT00480766
A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 60
- Registration Number
- NCT00480662
HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 312
- Registration Number
- NCT00480805
A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 618
- Registration Number
- NCT00479713
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 429
- Registration Number
- NCT00468312
A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 786
- Registration Number
- NCT00462748
Montelukast Back to School Asthma Study (0476-340)
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1162
- Registration Number
- NCT00461032
Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 440
- Registration Number
- NCT00457275
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 426
- Registration Number
- NCT00453063
An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)
Phase 3
Terminated
- Conditions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 11
- Registration Number
- NCT00449111
© Copyright 2024. All Rights Reserved by MedPath